Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00511940 · ClinicalTrials.gov registry record · Phase 2
Acamprosate in the Treatment of Binge-Eating Disorder
A Phase 2 study, sponsored by Lindner Center of HOPE.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00511940 is a Phase 2 study that has completed, run by Lindner Center of HOPE. The registered enrollment target is 40 participants.
The verdict
NCT00511940, a Phase 2 study, has completed, sponsored by Lindner Center of HOPE.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine the efficacy (how well it works), tolerability and safety of acomprosate compared with placebo in patients with binge eating disorder.
Interventions
- OTHER placebo
- DRUG acamprosate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2007-04 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00511940
The ClinicalTrials.gov registry entry for NCT00511940 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lindner Center of HOPE, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00511940 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00511940 about?
NCT00511940 is a clinical study titled "Acamprosate in the Treatment of Binge-Eating Disorder". The purpose of this research study is to determine the efficacy (how well it works), tolerability and safety of acomprosate compared with placebo in patients with binge eating disorder.
What is the current status of trial NCT00511940?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2007-04. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00511940?
The interventions under investigation include: placebo (OTHER), acamprosate (DRUG).
Who is sponsoring clinical trial NCT00511940?
This trial is sponsored by Lindner Center of HOPE, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.